Stratasys Ltd. announced last week enrollment is now open for 3DHEART, an investigator-initiated trial. 3DHEART, which stands for 3D Hearts Enabling A Randomized Trial, is a randomized, single-blind clinical trial to study the use of patient-specific 3-D-printed models in pre-operative planning for pediatric heart surgery. Stratasys is providing in-kind support with printing of the models to be used in the trial.

The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new recommendations on procedures employing gadolinium-based contrast agents, in which the committee recommended suspension of marketing authorization for four agents.

March, 10, 2017 - Medtronic announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has approved ...

To ensure imaging systems are operating safely and at optimum performance with appropriate and preventative maintenance, Toshiba Medical has introduced a customized PM Only Service Agreement to customers. The PM Only Service Agreement allows providers to fulfill and document that they are compliant with the Centers for Medicare & Medicaid (CMS) Directive and The Joint Commission’s (TJC) guidelines of ensuring all imaging equipment meets manufacturers’ specifications.

Medtronic plc announced the launch of the IN.PACT BTK study to evaluate the effectiveness of a drug-coated balloon (DCB) in patients with below-the-knee (BTK) peripheral arterial disease (PAD). This study will evaluate the IN.PACT 0.014 paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter. This is an investigational device, which uses Medtronic’s IN.PACT Admiral drug coating technology.